$5M Milestone Payment from Lilly Fuels VivoSim’s 500%+ Revenue Growth Guidance
Event summary
- VivoSim received a $5M milestone payment from Eli Lilly for the dosing of the first patient in Phase 2 studies of an inflammatory bowel disease drug.
- The company is eligible for up to $45M in additional milestone payments if key regulatory and commercial milestones are met.
- VivoSim anticipates over 500% revenue growth in FY2027 due to increasing demand for its NAMs models among pharmaceutical companies.
- The company’s NAMkind™ Liver spheroid model achieved a predictive accuracy of 91%, with 90% sensitivity, 95% specificity, and 99% precision under repeat-dose conditions.
The big picture
VivoSim’s milestone payment from Eli Lilly underscores the growing validation of its NAMs models in preclinical safety testing. The FDA’s encouragement of human-relevant NAMs is creating a favorable regulatory environment, positioning VivoSim to capitalize on increasing pharma demand for non-animal testing methods. The company’s aggressive revenue growth guidance reflects both its current traction and the broader industry shift toward more predictive, human-centric drug development tools.
What we're watching
- Regulatory Tailwinds
- The pace at which the FDA’s push for human-relevant NAMs drives pharma adoption of VivoSim’s models.
- Execution Risk
- Whether VivoSim can sustain its 500%+ revenue growth given the competitive landscape and dependency on milestone payments.
- Market Expansion
- How VivoSim’s expansion into new biotech modalities like antibody drug conjugates and gene therapies impacts its market position.
Related topics